Novartis Aktie
| 91,06CHF | -0,16CHF | -0,18% |
WKN: 904278 / ISIN: CH0012005267
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 89,22 |
| Novartis AG | 6,63 |
| Sandoz Family Foundation | 4,07 |
| UBS Asset Management Switzerland AG | 3,12 |
| Government Pension Fund - Global (The) | 2,55 |
| Vanguard Total International Stock Index Fund | 1,30 |
| Vanguard Developed Markets Index Fund | 0,80 |
| Vanguard Health Care Fund | 0,73 |
| Vanguard Institutional Total Intl. Stock Market Index Tr. II | 0,64 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 103 914 | 105 794 | 104 323 | 101 703 | 76 057 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,45 | 0,43 | 0,45 | 0,47 | 0,54 |
Bilanz (in Mio. CHF) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 28 570 | 26 229 | 41 656 | 34 149 | 25 654 |
| Summe Anlagevermögen | 86 095 | 90 619 | 82 155 | 78 508 | 61 729 |
| Summe Aktiva | 114 665 | 116 848 | 123 811 | 112 657 | 87 383 |
Bilanz (in Mio. CHF) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 28 225 | 33 462 | 28 268 | 25 821 | 22 176 |
| Summe Fremdkapital | 60 872 | 66 759 | 62 015 | 57 679 | 48 036 |
| Summe Eigenkapital | 53 793 | 50 090 | 61 796 | 54 978 | 39 347 |
| Summe Passiva | 114 665 | 116 848 | 123 811 | 112 657 | 87 383 |
Adresse
| Lichtstrasse 35, 4056 Basel | |
| Telefon | +41 (61) 324-11-11 |
| Internet | http://www.novartis.com |
Management
|
Aharon Gal
Chief Strategy & Growth Officer |
|
Ana de Pro Gonzalo
Independent Non-Executive Director |
|
Bridgette P. Heller
Independent Non-Executive Director |
|
Charles L. Sawyers
Independent Non-Executive Director |
|
Charlotte Pamer-Wieser
Secretary |
|
Daniel Hochstrasser
Independent Non-Executive Director |
|
Frans van Houten
Independent Non-Executive Director |
|
Hans Jörg Reinhardt
Chairman |
|
Harry Werner Kirsch
Chief Financial Officer |
|
John D. Young
Independent Non-Executive Director |
|
Karen L. Hale
Chief Legal Officer |
|
Kees Roks
Chief Audit Officer |
|
Klaus Moosmayer
Chief Ethics, Risk & Compliance Officer |
|
Linda Kanitra
Associate Director-Drug Development |
|
Linda M. Armstrong
Global Head-Respiratory Development Unit |
|
Marco Gadola
Senior Auditor |
|
Maria Victoria Cuevas-Pautonnier
Director-Investor Relations & Head-ESG |
|
Mary Elizabeth Doherty
Independent Non-Executive Director |
|
Michelle Weese
Executive Vice President-Corporate Affairs |
|
Nancy C. Andrews
Independent Non-Executive Director |
|
Patrice Bula
Lead Independent Non-Executive Director |
|
Patrick Horber
President-International |
|
Robert Kowalski
Chief People & Organization Officer |
|
Samir Shah
Global Head-Investor Relations |
|
Shreeram Aradhye
Chief Medical Officer & President-Development |
|
Simon Brown
Chief Learning Officer |
|
Simon E. Moroney
Vice Chairman |
|
Steffen Lang
President-Operations |
|
Ton Büchner
Independent Non-Executive Director |
|
Vasant Narasimhan
Chief Executive Officer |
|
William Thomas Winters
Independent Non-Executive Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
